antisense

An artists 3D rendering of cancerous blood cells among healthy red blood cells The cells fill the image and are of various
Biotech

Ono pays $280M upfront for Ionis' phase 2 blood cancer med

Japan's Ono Pharmaceutical is paying $280 million to acquire Ionis’ phase 2-stage antisense oligonucleotide for a rare type of blood cancer.
James Waldron Mar 12, 2025 6:30am
An artists depiction of DNA molecules made up of tiny particles

Oligonucleotide stops gene expansion driving Huntington's: study

Feb 12, 2025 2:00pm
Brain and money connected by a thread on a white background

Sanofi inks $400M biobucks deal for Alloy's antisense platform

Jan 8, 2025 5:08am
CRISPR Therapeutics

Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks

Oct 24, 2024 8:55am
Deal terminate tear up end deal scrap

Takeda axes Huntington’s pact, freeing Wave to pursue partners

Oct 16, 2024 8:07am
3d render of brain surrounded by pills

Denali reports new method to get ASOs across blood-brain barrier

Aug 14, 2024 2:00pm